Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

What Happened? Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...

Viatris (NASDAQ: VTRS) started trading publicly via a spinoff-merger. Ever since, the stock has been underperforming due to selling pressure.

Shares of Viatris Inc. VTRS slid 2.07% to $9.00 Wednesday, on what proved to be an all-around grim trading session for the ...